Short answer
FENNEC PHARMACEUTICALS INC. (FENC) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $15M (up 72.6% year over year) with net income of $201,000.
Q1 2026 key financials · XBRL
- Revenue
- $15M
- +72.6% YoY
- Net income
- $201,000
- +117.3% YoY
- Operating margin
- -0.8%
- EPS (diluted)
- $0.01
- +125.0% YoY
Source: XBRL data from the FENNEC PHARMACEUTICALS INC. (FENC) Q1 2026 10-Q on SEC EDGAR. USD.
FENNEC PHARMACEUTICALS INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $15.108M, up $6.357M YoY from $8.751M, driven by increased PEDMARK market penetration
- Net income $201K vs $1.165M net loss YoY; operating margin -0.8% vs -9.2%
- PEDMARK product sales, the sole reported product line, reached $15.108M
- Cash $40.179M vs $36.788M; operating cash flow $2.379M vs $(4.318)M YoY
- Near-term focus: additional Norgine launches in 2026 and Japan regulatory strategy; capital requirements remain substantially uncertain
Risk Factors
- No risk-factors section provided; supplied text covers Items 2–6 and signatures only
- No newly added risk factor identifiable from the provided filing text
- No material regulatory, legal, operational, competitive, market, or financial risk disclosed in the provided text
- New 2026 Equity Inducement Plan disclosed as Exhibit 10.1, without associated risk-factor discussion
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other FENNEC PHARMACEUTICALS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.